UBS upgraded Gossamer Bio (GOSS) to Buy from Neutral with a price target of $9, up from $1.25. The firm views the stock’s current risk/reward as “compelling” into the Phase 3 pulmonary arterial hypertension data in February 2026. The probability of success is underappreciated and seralutinib offers a “differentiated” mechanism of action with an inhaled route of administration, the analyst tells investors in a research note. UBS believes the novel mechanism has strong rationale from Gleevec data with improved safety from inhaled delivery.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOSS:
- Gossamer Bio’s Seralutinib: Promising Long-Term Therapy with Upcoming Catalysts
- Gossamer Bio Reports Q2 2025 Financial Results
- Gossamer Bio’s Promising Clinical Advancements and Strategic Positioning Earns Buy Rating
- Gossamer Bio reports Q2 EPS (17c) , consensus (18c)
- Gossamer Bio initiated with an Outperform at Scotiabank